At the time of writing, CRISPR Therapeutics AG [CRSP] stock is trading at $39.25, up 1.47%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRSP shares have gain 5.45% over the last week, with a monthly amount glided 3.78%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on February 14, 2025, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $99 from $60. Previously, TD Cowen upgraded its rating to Hold on February 12, 2025, and kept the price target unchanged to $35. On February 03, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $65 on the stock. Needham reiterated its Buy rating and decreased its price target to $84 on August 06, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $90 as its price target on August 02, 2024. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
For the past year, the stock price of CRISPR Therapeutics AG fluctuated between $30.04 and $67.88. Currently, Wall Street analysts expect the stock to reach $65 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $39.25 at the most recent close of the market. An investor can expect a potential return of 65.61% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
According to CRISPR Therapeutics AG [NASDAQ:CRSP], the company’s sales were 37.67M for trailing twelve months, which represents an 71.63% jump. Gross Profit Margin for this corporation currently stands at -2.59% with Operating Profit Margin at -13.13%, Pretax Profit Margin comes in at -10.57%, and Net Profit Margin reading is -10.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.2 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that CRISPR Therapeutics AG [NASDAQ:CRSP] has a current ratio of 15.64. Also, the Quick Ratio is 15.64, while the Cash Ratio stands at 1.97. Considering the valuation of this stock, the price to sales ratio is 89.99, the price to book ratio is 1.85.
Transactions by insiders
Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Mar 21 ’25 when 10031.0 shares were sold. Chief Operating Officer, Bruno Julianne completed a deal on Mar 21 ’25 to sell 1714.0 shares. Meanwhile, Chief Financial Officer Prasad Raju sold 2197.0 shares on Mar 21 ’25.
